Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) PT at $50.25

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have earned an average recommendation of “Moderate Buy” from the sixteen research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and fourteen have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $50.25.

A number of equities analysts recently issued reports on IDYA shares. Guggenheim raised their price target on IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Friday, July 17th. Royal Bank Of Canada decreased their price objective on IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating for the company in a research report on Tuesday, July 7th. Mizuho lowered their target price on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Wells Fargo & Company lifted their target price on IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a research note on Tuesday, April 14th.

Insider Buying and Selling at IDEAYA Biosciences

In related news, CAO Briseno Andres Ruiz sold 9,550 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total transaction of $382,095.50. Following the completion of the sale, the chief accounting officer directly owned 26,466 shares of the company’s stock, valued at $1,058,904.66. This trade represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On IDEAYA Biosciences

Large investors have recently bought and sold shares of the company. Janus Henderson Group PLC boosted its holdings in shares of IDEAYA Biosciences by 1.1% in the first quarter. Janus Henderson Group PLC now owns 7,265,253 shares of the company’s stock valued at $242,023,000 after acquiring an additional 78,797 shares in the last quarter. Vanguard Group Inc. raised its holdings in IDEAYA Biosciences by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 5,019,324 shares of the company’s stock worth $173,518,000 after purchasing an additional 97,116 shares in the last quarter. State Street Corp raised its holdings in IDEAYA Biosciences by 27.6% during the fourth quarter. State Street Corp now owns 4,134,641 shares of the company’s stock worth $142,935,000 after purchasing an additional 893,707 shares in the last quarter. Baker BROS. Advisors LP raised its holdings in IDEAYA Biosciences by 10.5% during the fourth quarter. Baker BROS. Advisors LP now owns 3,618,826 shares of the company’s stock worth $125,103,000 after purchasing an additional 343,382 shares in the last quarter. Finally, Fiera Capital Corp lifted its position in IDEAYA Biosciences by 32.6% in the fourth quarter. Fiera Capital Corp now owns 2,437,262 shares of the company’s stock valued at $84,256,000 after purchasing an additional 599,295 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Price Performance

Shares of NASDAQ:IDYA opened at $36.23 on Tuesday. The stock has a market cap of $3.18 billion, a P/E ratio of -22.64 and a beta of -0.09. The firm has a fifty day moving average price of $32.84 and a 200 day moving average price of $32.68. IDEAYA Biosciences has a 1-year low of $22.09 and a 1-year high of $40.58.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The business had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.04 million. During the same quarter in the previous year, the company posted ($0.82) EPS. The business’s revenue for the quarter was down 39.4% compared to the same quarter last year. Sell-side analysts expect that IDEAYA Biosciences will post -4.1 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.